Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 18, Issue 8, 2003, Pages 986-991

  Ushiyama, Atsushi ^a   Tanaka, Kazuo ^a   Aiba, Yuji ^a,b   Shiba, Tadahiko ^a   Takagi, Atsushi ^a   Mine, Tetsuya ^a   Koga, Yasuhiro ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Wakamoto Pharmaceutical   (Japan)

Author keywords

Clarithromycin; Helicobacter pylori; Lactobacillus; Probiotics

Indexed keywords

CLARITHROMYCIN; INTERLEUKIN 8; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL STRAIN; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ERADICATION THERAPY; GROWTH INHIBITION; HELICOBACTER INFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LACTOBACILLUS GASSERI; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0041352319     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2003.03102.x     Document Type: Article

References (22)

1. Marshall BJ. Helicobacter pylori. Am. J. Gastroenterol. 1994; 89: S116-28.
2. Greenwood D. Antibiotics and chemotherapeutic agents used in the therapy of bacterial infection. In: Collier L, Barlow A, Sussman M, eds. Topley & Wilson's Microbiology and microbial infections, ninth edn. London: Arnold, 1998; 195-230.
3. Maeda S, Yoshida H, Matsunaga H et al. Detection of Clarithromycin-resistant Helicobacter pylori strains by a preferential homoduplex formation assay. J. Clin. Microbiol. 2000; 38: 210-14.
4. Cayla R, Zerbib F, Talbi P, Mérgraud F, Lamouliatte H. Pre- and post-treatment clarithromycin resistance of Helicobacter pylori strains: key factor of treatment failure [Abstract]. Gut 1996; 37(Suppl.): A55.
5. Maeda S, Yoshida H, Ogura K, Kanai F, Shiratori Y, Omata M. Helicobacter pylori specific nested PCR assay for the detection of 23S rRNA mutation associated with clarithromycin resistance. Gut 1998; 43: 317-21.
6. Malfertheiner P, Mégraud F, O'Morain C et al. The European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Alim. Pharmacol. Ther. 2002; 16: 167-80.
7. Bhatia SJ, Kochar N, Abraham P, Nair NG, Mehra AP. Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro. J. Clin. Microbiol. 1989; 27: 2328-30.
8. Kabir AMA, Aiba Y, Takagi A, Kamiya S, Miwa T, Koga Y. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic routine model. Gut 1997; 41: 49-53.
9. Aiba Y, Suzuki N, Kabir AMA, Takagi A, Koga Y. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic mutine model. Am. J. Gastroenterol. 1998; 93: 2097-101.
10. Sakamoto I, Igarashi M, Kimura M, Takagi A, Miwa T, Koga Y. Suppressive effect of Lactobacillus gasseri OLL2716 (LG21) on Helicobacter pylori infection in humans. J. Antimicrobiol. Chemother. 2001; 47: 709-10.
11. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 1989; 243: 1464-6.
12. Baggiolini M, Walz Z, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J. Clin. Invest. 1989; 84: 1045-9.
13. Lindoholm C, Quiding-Järbrink M, Lönroth H, Svennerholm A-M. Induction of chemokine and cytokine responses by Helicobacter pylori in human stomach explants. Scand. J. Gastroenterol. 2001; 10: 1022-9.
14. Yakabi Y, Ro S, Okazaki R et al. Helicobacter pylori infection: Water extract of Helicobacter pylori stimulates interleukin-8 secretion by a human gastric epithelial cell line (JR-St) through protein tyrosine phosphorylation. J. Gastroenterol. Hepatol. 2000; 15: 263-70.
15. National Committee for Clinical Laboratory Standards. Performance standards for antibimicrobial susceptibility testing. VIth. Informational Suppl. M100S9. Villanova Pa: National Committee for Clinical Laboratory Standards; 1998.
16. Eckmann L, Chae Jung H, Schürer-Maly C, Panja A, Morzycka-Wroblenska E, Kagnoff MF. Differential cytokine expression by human intestinal epithelial cell lines: Regulated expression of Interleukin 8. Gastroenterology 1993; 105: 1689-97.
17. Debets-Ossenkopp YJ, Sparrius M, Kusters JG, Kolkman JJ, Vandenbroucke-Grauls CM. Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. Fed. Eur. Microbiol. Soc. Microbiol. Lett. 1996; 142: 37-42.
18. Lind T, Megraud F, Unge P et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 479-83.
19. Hoshiya S, Watanabe K, Tokunaga K et al. Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori. Japan. J. Gastroenterol. 2000; 35: 69-70.
20. Kandler O, Weiss N. Regular, nonosporing gram-positive rods. In: Sneath PHA, Mair NS, Sharpe ME, Holt JG, eds. Bergey's Manual of Systemic Bacteriology. Baltimore: Williams and Willikins, 1986; 1208-60.
21. Asahi M, Azuma T, Ito S et al. Helicobacter pylori CagA protein can be tyrosine phosphorylated in gastric epithelial cells. J. Exp. Med. 2000; 191: 587-92.
22. Versalovic J, Shortridge D, Kibler K et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 1996; 40: 477-80.